Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Adipocyte cell therapy targeting BMP signaling alleviates fibroadipose tissue deposition in secondary lymphedema.

Chen Z., Wu M., Nagam Hanumantharao S., Koirala P., Akbari Ghavimi SA., Siegel AE.

Animal Study on Systemic / IV, published in Mol Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Ther (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40988337
DOI
10.1016/j.ymthe.2025.09.034

Abstract (original English)

Secondary lymphedema is a chronic disease affecting an isolated limb following lymph node resection for cancer treatment. Management options are limited and onerous, leading to near-universal progression to subcutaneous fibroadipose tissue deposition. Here, we identify bone morphogenetic protein (BMP) ligands as mediators of fibroadipose tissue deposition through in vitro experiments with human lymphedema fluid and BMP-specific inhibitor. Systemic in vivo delivery of BMP inhibitor reduces fibroadipose tissue deposition in a mouse model of hindlimb secondary lymphedema. Considering systemic delivery may be undesirable for an anatomically isolated disease, we engineered a cell therapy using purified adipocytes, aiming for clinical translation in a resource- and time-constrained environment requiring only mechanical manipulation. We then devised a strategy for gene delivery into adipocytes and verified the secretion of the recombinant peptide inhibitor of BMP ligands. Upon in vivo delivery of the engineered adipocytes, we verified secretion of the BMP inhibitor and a reduction in fibroadipose tissue deposition in the mouse hindlimb. Our findings highlight BMPs as signaling mediators for fibroadipose tissue deposition and provide a blueprint for a cell therapy using genetically modified adipocytes for local drug delivery. This approach may be in a point-of-care strategy and potenti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMiceBone Morphogenetic ProteinsHumansSignal TransductionAdipocytesLymphedemaDisease Models, AnimalCell- and Tissue-Based TherapyAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research